Zobrazeno 1 - 10
of 24
pro vyhledávání: '"Rafael Hurtado-Monroy"'
Publikováno v:
Gaceta Médica de México, Vol 157, Iss 93 (2021)
Externí odkaz:
https://doaj.org/article/6675de34cf564671b178a569a8cf1805
Publikováno v:
Gaceta Médica de México. 157
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::71e722105d87f919ba1b5567534bb0d2
https://doi.org/10.24875/gmm.m21000469
https://doi.org/10.24875/gmm.m21000469
Publikováno v:
Acta Médica Grupo Ángeles. 18:177-184
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bc1618911379e5512a8fd13ddcf179db
https://doi.org/10.35366/93892
https://doi.org/10.35366/93892
Autor:
Andreas Hochhaus, Simon Purcell, Philippe Rousselot, Philipp le Coutre, Carlo Gambacorti-Passerini, Andrea Viqueira, Jeffrey H. Lipton, Michael W. Deininger, Rafael Hurtado Monroy, Michael J. Mauro, Richard E. Clark, Charles Chuah, Tim H. Brümmendorf, Anne Yver, Valentín García-Gutiérrez, Eric Leip, Vamsi Kota, Jorge E. Cortes, Dragana Milojkovic
Publikováno v:
Blood. 136:41-42
Introduction: BOS is approved for patients (pts) with Philadelphia chromosome-positive (Ph+) CML resistant/intolerant to prior therapy and pts with newly diagnosed Ph+ CP CML. Approval of first-line BOS was based on the primary results from the phase
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9d57860324bc709f6ca0f200ff99edf5
https://doi.org/10.1182/blood-2020-137393
https://doi.org/10.1182/blood-2020-137393
Publikováno v:
Blood. 134:5921-5921
Imatinib (IMA) total stop therapy has interesting worldwide results in selected patients (pts) with CML Ph+ who have achieved 4 to 5 log reduction of BCR/ABL copies, however there is no information of LDR. The observation that IMA intolerance induces
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b9afce44a155d4905f5c1fb5078de6d1
https://doi.org/10.1182/blood-2019-130873
https://doi.org/10.1182/blood-2019-130873
Autor:
Myrna Candelaria-Hernández, Pablo Vargas-Viveros, Jorge Luis Ángeles-Velázquez, Silvia Carrillo-Muñoz, Rafael Hurtado-Monroy
Publikováno v:
Clinical lymphoma, myelomaleukemia.
Background Over the past years, the survival of patients with Philadelphia-positive chronic myeloid leukemia (CML Ph + ) has increased as a result of therapy with tyrosin kinase inhibitors (TKIs). Intolerance to TKIs has been described in approximate
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c867fad25f95ae078717c6d016ff7509
https://pubmed.ncbi.nlm.nih.gov/27521331
https://pubmed.ncbi.nlm.nih.gov/27521331
Autor:
Myrna Candelaria, Judith Cruz, Rafael Hurtado-Monroy, Pablo Vargas-Viveros, Olga Gutierrez, Eduardo Cervera, Juan Labardini
Publikováno v:
Clinical Leukemia. 2:128-132
Background In an attempt to improve the cytogenetic and molecular response rate in Philadelphia chromosome–positive early chronic-phase CML, we compared the combination of imatinib plus low-dose cytarabine (Ara-C) versus imatinib alone. Patients an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d0d7126450e8fe8f04f80e032c3659f1
https://doi.org/10.3816/clk.2008.n.016
https://doi.org/10.3816/clk.2008.n.016
Autor:
Diego Sarre-Alvarez, Pablo Vargas-Viveros, Carlos Best, Myrna Candelaria-Hernández, Rafael Hurtado-Monroy, Judith Cruz-Vazquez, Montserrat Rojas, Berenice Vicente-Hernandez
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 16:S54
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::02266e9dd0418930281095729fdaa5be
https://doi.org/10.1016/j.clml.2016.07.078
https://doi.org/10.1016/j.clml.2016.07.078
Autor:
Carlo Gambacorti Passerini, Laura, Antolini, Rocco, Piazza, François, Guilhot, Michael, Deininger, Fava, Carmen, Arnon, Nagler, Enrica, Morra, Elisabetta, Abruzzese, Anna, D'Emilio, Fabio, Stagno, le Coutre, Philipp D., Rafael Hurtado Monroy, Valeria, Santini, Fabrizio, Pane, Pilar, Giraldo, Sarit, Assouline, Durosinmi, Muheez A., Onno, Leeksma, Enrico Maria Pogliani, Francesca, Pavesi, Miriam, Puttini, Christian, Rizzo, Ilaria, Dilda, Silvia, Mori, Dong Wook Kim, Maria Grazia Valsecchi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od_______970::7cd6028efe82051a1d60b93706fbf531
http://hdl.handle.net/2318/157359
http://hdl.handle.net/2318/157359
Autor:
Carlo, Gambacorti-Passerini, Laura, Antolini, François-Xavier, Mahon, Francois, Guilhot, Michael, Deininger, Carmen, Fava, Arnon, Nagler, Chiara Maria, Della Casa, Enrica, Morra, Elisabetta, Abruzzese, Anna, D'Emilio, Fabio, Stagno, Philipp, le Coutre, Rafael, Hurtado-Monroy, Valeria, Santini, Bruno, Martino, Fabrizio, Pane, Andrea, Piccin, Pilar, Giraldo, Sarit, Assouline, Muheez A, Durosinmi, Onno, Leeksma, Enrico Maria, Pogliani, Miriam, Puttini, Eunjung, Jang, Josy, Reiffers, Rocco, Piazza, Maria Grazia, Valsecchi, Dong-Wook, Kim
BackgroundImatinib slows development of chronic myeloid leukemia (CML). However, available information on morbidity and mortality is largely based on sponsored trials, whereas independent long-term field studies are lacking.Patients and MethodsConsec
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::77bb0c346db4a02f4ab23a28fdd7358d
http://hdl.handle.net/11588/573920
http://hdl.handle.net/11588/573920